Global Weight Loss Drugs Market
世界の減量薬市場 : 製品タイプ（粉末および丸薬、液体、注射）、薬剤タイプ［処方薬および店頭（OTC）薬］、流通チャネル（オンラインおよびオフライン）、エンドユーザー（18歳未満、18歳以上）、40歳、40 ～ 50歳、50歳以上）、地域別分析、市場規模と動向 – 2029年までの予測
Global Weight Loss Drugs Market: Analysis By Product Type (Powders and Pills, Liquids, and Injection), By Drug Type (Prescription Drugs and Over The Counter (OTC) Drugs), By Distribution Channel (Online and Offline), By End User (Under 18 Years, 18-40 Years, 40-50 Years and Above 50 Years), By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029
Today, it’s the fifth-leading risk factor cited by the WHO for contributing as a primary cause of death globally. Lifestyle changes, sedentary habits, and unhealthy dietary patterns have contributed to the demand for effective weight management strategies, driving the market further. About 100 million people in the US are obese and only 3 million of them are receiving pharmaceutical treatment. The global weight loss drugs market was valued at US$3.83 billion in 2023, and is expected to be worth US$44.12 billion in 2029.
世界の減量薬市場は2023年に38億3,000万米ドルと評価され、2029年には441億2,000万米ドルになると予想されています。
The key players of the global weight loss drugs market are:
Merck KGaA
GlaxoSmithKline Plc Eli Lilly and Company
Boehringer Ingelheimv Novo Nordisk A/S
Rhythm Pharmaceuticals Inc.
Amgen Inc.
Viking Therapeutics, Inc.
Currax Pharmaceuticals LLC
VIVUS LLC
Mergers and acquisitions among pharmaceutical companies have become commonplace in the weight loss drugs market. These strategic moves aim to strengthen product portfolios, expand market reach, and capitalize on synergies. Companies may also collaborate with academic institutions or biotechnology firms to leverage cutting-edge research and development capabilities.